Regulus Therapeutics, Inc.

As of March 11, 2022, Regulus Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," indicated by poor financial metrics such as a Price to Book Value of 8.24, negative ROCE of -1237.25%, and underperformance compared to peers, despite a year-to-date stock return of 416.46%.

As of March 11, 2022, Regulus Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in its negative P/E ratio, alarming ROCE of -1237.25%, and high Price to Book Value of 8.24, despite a remarkable year-to-date stock return of 415.19%.

As of May 27, 2025, the trend is bullish with strong indicators like MACD and moving averages supporting this view, although the RSI suggests potential overbought conditions.

As of March 2022, the management team of Regulus Therapeutics, Inc. includes Dr. Stelios Papadopoulos (Independent Chairman), Mr. Joseph Hagan (President and CEO), and several Independent Directors: Dr. David Baltimore, Ms. Kathryn Collier, Mr. Jake Nunn, Dr. William Rastetter, and Dr. Hugh Rosen. This team provides executive leadership and governance for the company.

Regulus Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs that target microRNAs for various diseases. It has a market cap of approximately $567.72 million and reported a net profit loss of $10 million in March 2025.

As of Jun 18, Regulus Therapeutics, Inc. has a market capitalization of 567.72 million, with net sales of 0.00 million and a net profit of -47.52 million over the last four quarters. The company reported shareholder's funds of 76.41 million and total assets of 84.18 million as of Dec 24.